陳寧南, 萬 強(qiáng)
(1江西省人民醫(yī)院急診科, 2江西中醫(yī)藥大學(xué)附屬醫(yī)院心血管病科, 江西 南昌 330006)
小檗堿減輕幽門螺桿菌誘導(dǎo)的人胃黏膜上皮細(xì)胞損傷*
陳寧南1, 萬 強(qiáng)2△
(1江西省人民醫(yī)院急診科,2江西中醫(yī)藥大學(xué)附屬醫(yī)院心血管病科, 江西 南昌 330006)
目的探討小檗堿(Ber)對幽門螺桿菌(Hp)誘導(dǎo)的人胃黏膜上皮細(xì)胞GES-1損傷的保護(hù)作用及機(jī)制。方法采用Hp感染GES-1細(xì)胞,加入小檗堿(5,10和20 μmol/L)和細(xì)胞外調(diào)節(jié)蛋白激酶(ERK1/2)抑制劑PD98059(20 μmol/L)共培養(yǎng)。MTT法檢測細(xì)胞活力,流式細(xì)胞術(shù)檢測細(xì)胞凋亡,ELISA法檢測細(xì)胞白細(xì)胞介素(IL)-1β及IL-8的水平,比色法檢測細(xì)胞乳酸脫氫酶(LDH)活性并以Western blot法檢測細(xì)胞Bax、Bcl-2、p-ERK1/2的蛋白水平。結(jié)果與對照組比較,Hp可抑制GES-1細(xì)胞活力、促進(jìn)GES-1細(xì)胞凋亡、誘導(dǎo)GES-1細(xì)胞分泌IL-1β和IL-8、增加LDH活性、增加GES-1細(xì)胞內(nèi)p-ERK1/2及Bax蛋白水平并降低Bcl-2蛋白水平,差異均有統(tǒng)計學(xué)顯著性(P<0.05);與Hp感染組比較,中、高劑量小檗堿均可逆轉(zhuǎn)Hp對GES-1細(xì)胞活力、細(xì)胞凋亡、細(xì)胞IL-1β及IL-8分泌、LDH活性和GES-1細(xì)胞內(nèi)p-ERK1/2、Bax及Bcl-2蛋白水平的影響,差異均有統(tǒng)計學(xué)顯著性(P<0.05);與高劑量小檗堿組比較,PD98059聯(lián)合小檗堿可進(jìn)一步逆轉(zhuǎn)Hp對GES-1細(xì)胞上述指標(biāo)的影響,差異均有統(tǒng)計學(xué)顯著性(P<0.05)。結(jié)論小檗堿可通過抗炎、增加細(xì)胞活力和抗凋亡來減輕Hp誘導(dǎo)的GES-1細(xì)胞損傷,其機(jī)制可能與抑制ERK1/2通路有關(guān)。
小檗堿; 幽門螺桿菌; 細(xì)胞外調(diào)節(jié)蛋白激酶1/2; 人胃黏膜上皮細(xì)胞
幽門螺桿菌(Helicobacterpylori,Hp)是革蘭陰性微需氧菌,生存于胃和十二指腸內(nèi),感染后誘發(fā)的胃黏膜慢性炎癥可損傷胃黏膜上皮細(xì)胞,發(fā)展為慢性活動性胃炎、胃和十二指腸潰瘍,甚至參與胃淋巴瘤與胃癌的形成[1]。臨床上多使用2種抗生素加質(zhì)子泵抑制劑的三聯(lián)療法治療Hp感染,但長期使用可顯著增加Hp耐藥,導(dǎo)致Hp根除率下降[2]。中醫(yī)藥對于慢性胃炎的療效確切且副作用低,因此,積極研究并開發(fā)抑制Hp的中藥或單體具有重要的醫(yī)學(xué)價值。小檗堿(berberine,Ber)又名黃連素,是從黃連、黃柏和伏牛花等中藥植物中提取的異喹啉生物堿,體外對多種革蘭陽性及陰性菌均具顯著的抑菌作用,臨床廣泛用于治療胃腸感染和細(xì)菌性痢疾等消化性疾病[3]。研究表明,小檗堿可顯著抑制由Hp感染導(dǎo)致的慢性胃炎的形成[4],但具體分子機(jī)制有待進(jìn)一步研究。細(xì)胞外信號調(diào)節(jié)激酶1/2(extracellular signal-regulated kinase 1/2,ERK1/2)信號通路參與了調(diào)控炎癥反應(yīng)、細(xì)胞增殖及細(xì)胞凋亡等多種生理及病理進(jìn)程[5]。為進(jìn)一步探討小檗堿在慢性胃炎中的可能作用靶點,本研究采用Hp感染人胃黏膜上皮GES-1細(xì)胞,加入小檗堿及ERK1/2選擇性阻滯劑PD98059干預(yù),探討小檗堿對Hp誘導(dǎo)GES-1細(xì)胞損傷的影響及可能機(jī)制,為小檗堿的臨床應(yīng)用提供實驗依據(jù)。
GES-1細(xì)胞株購于上海生博生物醫(yī)藥科技有限公司;鹽酸小檗堿(HPLC≥98%)和MTT干粉均購自Sigma;Hp菌株購自ATCC細(xì)胞庫;RPMI-1640培養(yǎng)基購自Invitrogen;PD98059購自Tocris Bioscience;胎牛血清購自Gibco;抗Bax、Bcl-2、t-ERK1/2、p-ERK1/2及β-actin抗體均購自Abcam;白細(xì)胞介素(interleukin,IL)-1β和IL-8 ELISA試劑盒均購自eBioscience;乳酸脫氫酶(lactic dehydrogenase,LDH)試劑盒購自南京建成生物工程研究所;Annexin V-FITC細(xì)胞凋亡試劑盒購自Beyotime。ST16型冷凍高速離心機(jī)購自Thermo;MK3型酶標(biāo)儀、164-5050型電泳儀和2401型CO2細(xì)胞培養(yǎng)箱均購自Bio-Rad;FACSCalibur型流式細(xì)胞儀購自BD;DMI3000B型熒光倒置顯微鏡購自Leica。
2.1Hp與GES-1細(xì)胞共培養(yǎng)及實驗分組 將GES-1細(xì)胞接種至培養(yǎng)皿,置于含10% 胎牛血清的RPMI-1640培養(yǎng)基,于37 ℃、5% CO2培養(yǎng)箱內(nèi)培養(yǎng),細(xì)胞融合80%時傳代。以無菌PBS液重懸Hp,2 000 r/min離心5 min,棄上清液后加含2% 胎牛血清的RPMI-1640培養(yǎng)基,調(diào)整Hp菌液濃度為1×1012CFU/L。GES-1細(xì)胞分為6組:(1)對照(control)組:只加RPMI-1640培養(yǎng)基;(2)Hp感染(Hp)組:加Hp菌液,以細(xì)菌∶細(xì)胞為200∶1的比例共培養(yǎng)24 h;(3)~(5)分別為小檗堿低劑量(Hp+Ber 5 μmol/L)、小檗堿中劑量(Hp+Ber 10 μmol/L)和小檗堿高劑量(Hp+Ber 20 μmol/L)組:分別以小檗堿(5、10和20 μmol/L)[6]預(yù)處理GES-1細(xì)胞30 min后,再加Hp菌液,以細(xì)菌∶細(xì)胞為200∶1的比例(預(yù)實驗結(jié)果)共培養(yǎng)24 h;(6)PD98059組:以小檗堿20 μmol/L預(yù)處理GES-1細(xì)胞30 min后,加20 μmol/L PD98059[7]處理細(xì)胞30 min,再加Hp菌液以細(xì)菌∶細(xì)胞為200∶1的比例共培養(yǎng)24 h。
2.2MTT法檢測細(xì)胞活力 將GES-1細(xì)胞按每孔1×104個接種至96孔板,每組設(shè)6個復(fù)孔,24 h后撤去血清,加入5 g/L的MTT液20 μL,培養(yǎng)4 h,棄上清液后,每孔加DMSO 150 μL,振蕩溶解10 min,以570 nm為測定波長檢測吸光度(A)值。細(xì)胞活力抑制率(%)=[1-(實驗組A值/對照組A值)]×100%。
2.3流式細(xì)胞術(shù)檢測細(xì)胞凋亡 將GES-1細(xì)胞按每孔2×105個接種至12孔板,24 h后換無血清的RPMI-1640培養(yǎng)基培養(yǎng)24 h,1 000 r/min離心5 min,加Annexin V-FITC及PI按說明書方法孵育,1 h內(nèi)用流式細(xì)胞儀檢測GES-1細(xì)胞的凋亡率。
2.4LDH活性及IL-1β和IL-8水平的測定 將GES-1細(xì)胞以1×104個接種至培養(yǎng)皿,收集上清液,用比色法測LDH活性,ELISA檢測IL-1β及IL-8水平,檢測按照試劑盒說明書操作。
2.5Western blot檢測Bax、Bcl-2和p-ERK1/2蛋白的表達(dá) 提取GES-1細(xì)胞總蛋白,BCA法測蛋白濃度,100 ℃變性蛋白5 min,凝膠電泳,蛋白半干轉(zhuǎn)印至PVDF膜,5%脫脂牛奶封閉2 h,加相應(yīng) I 抗(1∶1 000)于4 ℃孵育后,再加 II 抗(1∶2 000)于室溫下孵育,ECL顯影并拍照。Quantity One軟件條帶分析灰度,以β-actin作內(nèi)參照。
采用SPSS 13.0統(tǒng)計軟件進(jìn)行數(shù)據(jù)分析,實驗數(shù)據(jù)采用均數(shù)±標(biāo)準(zhǔn)差(mean±SD)表示,多組間比較采用單因素方差分析(one-way ANOVA),兩組間比較用Bonferroni法,以P<0.05為差異有統(tǒng)計學(xué)意義。
與對照組比較,Hp可顯著抑制GES-1細(xì)胞活力,差異有統(tǒng)計學(xué)顯著性(P<0.05);與Hp感染組比較,小檗堿中、高劑量干預(yù)均可逆轉(zhuǎn)Hp抑制GES-1細(xì)胞活力的作用,差異均有統(tǒng)計學(xué)顯著性(P<0.05);與小檗堿高劑量組比較,加入PD98059干預(yù)可進(jìn)一步逆轉(zhuǎn)Hp抑制GES-1細(xì)胞活力的作用,差異有統(tǒng)計學(xué)顯著性(P<0.05),見表 1。
與對照組比較,Hp可顯著誘導(dǎo)GES-1細(xì)胞凋亡,差異有統(tǒng)計學(xué)顯著性(P<0.01);與Hp感染組比較,小檗堿中、高劑量干預(yù)均可逆轉(zhuǎn)Hp誘導(dǎo)的GES-1細(xì)胞凋亡,差異均有統(tǒng)計學(xué)顯著性(P<0.05);與小檗堿高劑量組比較,加入PD98059干預(yù)可進(jìn)一步逆轉(zhuǎn)Hp對GES-1細(xì)胞凋亡的影響,差異有統(tǒng)計學(xué)顯著性(P<0.05),見表1。
表1小檗堿及PD98059對GES-1細(xì)胞活力及凋亡的影響
Table 1. The effects of berberine and PD98059 on the viability and apoptotic rate of GES-1 cells (Mean±SD.n=3)
GroupInhibitoryrateofcellactivity(%)Apoptoticrate(%)Control-10.53±2.18Hp41.63±6.14*36.47±5.52**Hp+Ber5μmol/L40.55±6.0235.91±5.97Hp+Ber10μmol/L28.13±5.19#28.13±4.48#Hp+Ber20μmol/L21.69±4.52#22.63±4.71#PD9805915.34±4.27#▲14.12±3.29#▲
*P<0.05,**P<0.01vscontrol group;#P<0.05vsHp group;▲P<0.05vsHp+Ber 20 μmol/L group.
與對照組比較,Hp可增加GES-1細(xì)胞上清中IL-1β和IL-8水平并增加LDH活性,差異均有統(tǒng)計學(xué)顯著性(P<0.05);與Hp感染組比較,小檗堿中、高劑量干預(yù)均可逆轉(zhuǎn)Hp對GES-1細(xì)胞上清中IL-1β及IL-8水平及LDH活性的影響,差異均有統(tǒng)計學(xué)顯著性(P<0.05);與小檗堿高劑量組比較,加入PD98059干預(yù)可進(jìn)一步增強(qiáng)小檗堿的作用,IL-1β、IL-8水平及LDH活性進(jìn)一步降低,差異均有統(tǒng)計學(xué)顯著性(P<0.05),見表2。
表2小檗堿及PD98059對GES-1細(xì)胞LDH活性及IL-1β、IL-8水平的影響
Table 2. The effects of berberine and PD98059 on LDH activity, IL-1β and IL-8 levels of GES-1 cells (Mean±SD.n=3)
GroupLDH(U/L)IL-1β(ng/L)IL-8(ng/L)Control462.73±51.534.47±1.3620.76±6.61 Hp1481.27±130.62*90.13±9.04*215.88±23.73*Hp+Ber5μmol/L1476.52±137.8388.78±9.32212.50±21.85Hp+Ber10μmol/L1206.18±125.23#61.27±8.52#168.03±17.63#Hp+Ber20μmol/L871.86±103.24#37.38±7.98#104.74±12.47#PD98059609.54±82.13#▲20.42±5.59#▲59.36±10.71#▲
*P<0.05vscontrol group;#P<0.05vsHp group;▲P<0.05vsHp+Ber 20 μmol/L group.
與對照組比較,Hp可增加GES-1細(xì)胞中Bax及p-ERK1/2的蛋白水平,并降低Bcl-2的蛋白水平,差異均有統(tǒng)計學(xué)顯著性(P<0.05);與Hp感染組比較,小檗堿中、高劑量干預(yù)均可逆轉(zhuǎn)Hp對GES-1細(xì)胞中Bax、p-ERK1/2和Bcl-2蛋白水平的影響,差異均有統(tǒng)計學(xué)顯著性(P<0.05);與小檗堿高劑量組比較,加入PD98059干預(yù)可進(jìn)一步增強(qiáng)小檗堿的作用,差異均有統(tǒng)計學(xué)顯著性(P<0.05),見圖1。
1983年,Marshall等[8]利用螺桿菌培養(yǎng)技術(shù)從慢性活動性胃炎患者的胃黏膜組織中首次成功分離Hp。Hp是目前所知唯一能在人胃中生存的微生物種類[9]。Hp感染后產(chǎn)生的尿素酶、黏液酶、脂多糖、磷脂酶、蛋白酶和過氧化物歧化酶等致病因子,可降低正常胃黏膜分泌的黏液中黏蛋白含量, 破壞黏液完整性,從而破壞胃黏膜屏障,導(dǎo)致慢性胃炎的發(fā)生[10]。
Hp還可破壞胃黏膜上皮的完整性。Hp感染后導(dǎo)致胃黏膜上皮細(xì)胞增殖與凋亡的平衡紊亂,可引起慢性胃炎和消化性潰瘍等相關(guān)疾病的發(fā)生。Bax和Bcl-2是bcl-2基因家族中對于細(xì)胞凋亡起了調(diào)控作用的重要成員。bax是促凋亡基因,位于細(xì)胞質(zhì),可直接結(jié)合到線粒體膜上,改變細(xì)胞膜通透性,引起細(xì)胞色素C釋放并激活caspases家族,從而促進(jìn)細(xì)胞凋亡;bcl-2是抑凋亡基因,可通過抑制細(xì)胞線粒體膜電位的下降,減少細(xì)胞色素C釋放進(jìn)入細(xì)胞質(zhì),從而抑制細(xì)胞凋亡[11-13]。本研究中MTT檢測結(jié)果顯示,Hp可顯著抑制GES-1細(xì)胞活力;流式細(xì)胞術(shù)檢測結(jié)果顯示Hp可增加GES-1細(xì)胞凋亡;Western blot檢測結(jié)果顯示Hp可增加GES-1細(xì)胞內(nèi)Bax蛋白水平并減少Bcl-2蛋白水平,證實Hp可抑制GES-1細(xì)胞生長,并通過調(diào)控Bax及Bcl-2水平而促進(jìn)GES-1細(xì)胞凋亡。
Figure 1. The effects of berberine and PD98059 on the protein levels of Bax, Bcl-2 and p-ERK1/2 in the GES-1 cells. A: control group; B: Hp group; C: Hp+Ber 5 μmol/L group; D: Hp+Ber 10 μmol/L group; E: Hp+Ber 20 μmol/L group; F: PD98059 group. Mean±SD.n=3.*P<0.05vscontrol group;#P<0.05vsHp group;▲P<0.05vsHp+Ber 20 μmol/L group.
圖1小檗堿及PD98059對GES-1細(xì)胞Bax、Bcl-2和p-ERK1/2蛋白水平的影響
Hp感染可誘導(dǎo)胃黏膜上皮炎癥細(xì)胞的浸潤,釋放IL-1β和IL-8等前炎癥介質(zhì),IL-1β和IL-8觸發(fā)的級聯(lián)反應(yīng)可進(jìn)一步導(dǎo)致細(xì)胞間黏附分子1和上皮細(xì)胞黏附分子過度活化,引起胃黏膜固有層中性粒細(xì)胞、淋巴細(xì)胞和單核細(xì)胞等聚集從而促進(jìn)慢性胃炎的發(fā)生[14]。LDH是一種存在于機(jī)體所有組織細(xì)胞的細(xì)胞質(zhì)內(nèi)的糖酵解酶,當(dāng)細(xì)胞受到損傷時細(xì)胞質(zhì)內(nèi)氧依賴性酶及細(xì)胞膜結(jié)構(gòu)均發(fā)生改變,增加細(xì)胞膜通透性,使細(xì)胞外液LDH漏出量增加,因此LDH活性的高低可反映細(xì)胞損傷的程度[15]。本研究中ELISA法及比色法檢測結(jié)果顯示,Hp可增加GES-1細(xì)胞IL-1β及IL-8水平并增加LDH活性,證實Hp可誘導(dǎo)炎癥導(dǎo)致GES-1細(xì)胞損傷。
既往研究表明,小檗堿在體內(nèi)及體外均具有較強(qiáng)的抗Hp感染作用[4]。隨著抗生素在Hp根除治療中廣泛應(yīng)用,Hp多重耐藥的發(fā)生率日益上升。主動外排系統(tǒng)hefA基因的高表達(dá)可導(dǎo)致體外人工誘導(dǎo)Hp多重耐藥的發(fā)生[16],小檗堿可通過下調(diào)hefA mRNA的表達(dá),顯著減輕四環(huán)素和阿莫西林等抗生素引起的Hp多重耐藥的發(fā)生[17]。ERK1/2信號通路是細(xì)胞絲裂原活化蛋白激酶(mitogen-activated protein kinase,MAPK)通路家族的重要成員,可以被生長因子、離子射線和過氧化氫等激活,參與了調(diào)控炎癥反應(yīng)、細(xì)胞增殖及凋亡等多種生理及病理進(jìn)程[5]。PD98059是常用的ERK1/2高效選擇性阻滯劑,能特異地抑制MAPK激酶介導(dǎo)的MAPK活化,不會直接抑制ERK1/2[18]。本研究結(jié)果表明,Hp可顯著增加GES-1細(xì)胞中p-ERK1/2的蛋白水平;小檗堿干預(yù)后可顯著逆轉(zhuǎn)Hp對GES-1細(xì)胞的影響;加入PD98059干預(yù)可進(jìn)一步增強(qiáng)小檗堿的藥理作用,提示小檗堿減輕Hp誘導(dǎo)的GES-1細(xì)胞損傷的機(jī)制可能與抑制ERK1/2通路有關(guān)。
[1] Bagirova M, Allahverdiyev AM, Abamor ES, et al. An overview of challenges to eradication ofHelicobacterpyloriinfection and future prospects[J]. Eur Rev Med Pharmacol Sci, 2017, 21(9):2199-2219.
[2] Chunlertlith K, Limpapanasit U, Mairiang P, et al. Outcomes of a randomized controlled trial comparing modified high dose omeprazole and amoxicillin triple therapy with standard triple therapy forHelicobacterpylorieradication[J]. Asian Pac J Cancer Prev, 2017, 18(4):927-932.
[3] Imenshahidi M, Hosseinzadeh H. Berberis vulgaris and berberine: an update review[J]. Phytother Res, 2016, 30(11):1745-1764.
[4] Lin YH, Lin JH, Chou SC, et al. Berberine-loaded targeted nanoparticles as specificHelicobacterpylorieradication therapy:invitroandinvivostudy[J]. Nanomedicine (Lond), 2015, 10(1):57-71.
[5] Liu N, Kong T, Chen X, et al. Ubiquitin-specific protease 14 regulates LPS-induced inflammation by increasing ERK1/2 phosphorylation and NF-κB activation[J]. Mol Cell Biochem, 2017, 431(1-2):87-96.
[6] Shi HL, Wu XJ, Liu Y, et al. Berberine counteracts enhanced IL-8 expression of AGS cells induced by evodiamine[J]. Life Sci, 2013, 93(22):830-839.
[7] Wang Y, Liu J, Cui J, et al. ERK and p38 MAPK signaling pathways are involved in ochratoxin A-induced G2phase arrest in human gastric epithelium cells[J]. Toxicol Lett, 2012, 209(2):186-192.
[8] Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration[J]. Lancet, 1984, 1(8390):1311-1315.
[9] 黃 珊, 賴仁發(fā), 鐘麗珍. 幽門螺桿菌感染對人牙齦組織細(xì)胞凋亡的影響[J]. 中國病理生理雜志, 2017, 33(7):1323-1327.
[10] Diaconu S, Predescu A, Moldoveanu A, et al.Helicobac-terpyloriinfection: old and new[J]. J Med Life, 2017, 10(2):112-117.
[11] Zheng JH, Viacava FA, Kriwacki RW, et al. Discoveries and controversies in BCL-2 protein-mediated apoptosis[J]. FEBS J, 2016, 283(14):2690-2700.
[12] 毛挺挺, 鄭亞華, 方紅波, 等. Bcl-2和PCNA表達(dá)在大鼠成肌細(xì)胞氧化應(yīng)激損傷中的作用[J]. 中國病理生理雜志, 2017, 33(5):935-938.
[13] 王少敏, 葉 孟, 倪曙民, 等.bcl-3基因通過cyclin D1及Bax蛋白影響人結(jié)腸癌RKO細(xì)胞的凋亡[J]. 中國病理生理雜志, 2017, 33(5):939-943.
[14] Panpetch W, Spinler JK, Versalovic J, et al. Characterization of Lactobacillus salivarius strains B37 and B60 capable of inhibiting IL-8 production inHelicobacterpylori-stimulated gastric epithelial cells[J]. BMC Microbiol, 2016, 16(1):242.
[15] Skory CD, Ibrahim AS. Native and modified lactate dehydrogenase expression in a fumaric acid producing isolate Rhizopus oryzae 99-880[J]. Curr Genet, 2007, 52(1):23-33.
[16] Liu ZQ, Zheng PY, Yang PC. Efflux pump genehefAofHelicobacterpyloriplays an important role in multidrug resistance[J]. World J Gastroenterol, 2008, 14(33):5217-5222.
[17] Huang YQ, Huang GR, Wu MH, et al. Inhibitory effects of emodin, baicalin, schizandrin and berberine onhefAgene: treatment ofHelicobacterpylori-induced multidrug resistance[J]. World J Gastroenterol, 2015, 21(14):4225-4231.
[18] Crews CM, Alessandrini A, Erikson RL. The primary structure of MEK, a protein kinase that phosphorylates theERKgene product[J]. Science, 1992, 258(5081):478-480.
Effect of berberine on Helicobacter pylori-induced human gastric epithe-lial cells injury
CHEN Ning-nan1, WAN Qiang2
(1EmergencyDepartment,JiangxiProvincialPeople’sHospital,2DepartmentofMedicalCardiology,TheAffiliatedHospitalofJiangxiUniversityofTraditionalChineseMedicine,Nanchang330006,China.E-mail:wanqiang109559140@163.com)
AIM: To investigate the effect of berberine (Ber) onHelicobacterpylori(Hp)-induced human gastric epithelial cells (GES-1) injury and the underlying mechanism.METHODSBerberine (5, 10 and 20 μmol/L) and PD98059 (20 μmol/L), a selective inhibitor of extracellular regulated protein kinases (ERK)1/2 signaling pathway, were added to Hp-infected GES-1 cells. The cell activity and apoptosis, the levels of interleukin (IL)-1β and IL-8, lactic dehydrogenase (LDH) activity and the protein levels of Bax, Bcl-2 and p-ERK1/2 in the GES-1 cells were determined by MTT assay, flow cytometry, ELISA, colorimetry and Western blot, respectively.RESULTSCompared with control group, Hp significantly inhibited the cell activity, increased the apoptotic rate, LDH activity, IL-1β and IL-8 levels, the Bax and p-ERK1/2 protein levels but decreased the Bcl-2 protein level in GES-1 cells (P<0.05). However, these effects of Hp were reversed by berberine at medium-dose and high-dose, as compared with the Hp-infected GES-1 cells (P<0.05). Moreover, the protective effects of berberine were significantly enhanced by the co-incubation of berberine with PD98059, as compared with the berberine at higher dose (P<0.05).CONCLUSIONBerberine may attenuate Hp-induced human gastric epithelial GES-1 cells injury by anti-inflammation, promoting cell growth and anti-apoptosis via the inhibition of ERK1/2 signaling pathway.
Berberine;Helicobacterpylori; Extracellular regulated protein kinase 1/2; Human gastric epithelial cells
1000- 4718(2017)12- 2283- 04
2017- 06- 21
2017- 08- 02
國家自然科學(xué)基金資助項目(No. 81660770);江西省自然科學(xué)基金資助項目(No. 20161BAB215256);江西省衛(wèi)生計生委科技計劃(No. 20171105);江西省衛(wèi)生計生委中醫(yī)藥科研課題(No. 2016A083)
△通訊作者 Tel: 0791-86360490; E-mail: wanqiang109559140@163.com
R285.5; R363
A
10.3969/j.issn.1000- 4718.2017.12.028
(責(zé)任編輯: 盧 萍, 余小慧)